

**Annual General Meeting  
7 November 2002**


**Fraser Ainsworth  
Chairman**

**Bionomics**

# Market Capitalisation

Index of Bionomics' market capital relative to the ASX Healthcare and Biotech Index and to a sample of similar ASX-listed stocks with a market capitalisation of \$20-\$50 million

Index 100 at end January 2002 (data points at months end)



Bionomics

Bionomics  Limited

# Positive Outlook

Fundamentals in place:

- First revenue
- Balanced portfolio
- Well-defined strategy
- Experienced team to execute strategy

# **Annual General Meeting**

## **7 November 2002**

**Deborah Rathjen**  
**CEO & Managing Director**

**Bionomics**

# Business Highlights

**30 January 2002**

Hybrigen Inc. deal to collaborate on novel angiogenesis drug target

**9 May 2002**

Johnson & Johnson collaboration to validate Bionomics' angiogenesis drug targets

**1 October 2002**

Nanogen deal to develop epilepsy diagnostic

**12 March 2002**

Genmab deal to co-develop human antibodies for angiogenesis targets

**29 May 2002**

Bionomics and Genmab expand collaboration to third target

# Corporate Highlights

**10 December 2001**  
Francis Placanica  
appointed Vice President,  
Business Development

**11 March 2002**  
Move to new  
Research Facility,  
Thebarton  
Bioscience  
Precinct

**11 April 2002**  
Dr Ralf Brandt  
appointed Head of  
Cell Biology

**2 October 2002**  
American Depository  
Receipts launched on  
US OTC exchange

**17 December 2001**  
Dr Gabriel  
Kremmidiotis  
appointed Head of  
Bioinformatics

**14 March 2002**  
Dr Andy Dunbar  
appointed Head  
of Proteomics

# Research & Development Highlights

**4 December 2001**  
\$1.74 million Federal  
Government breast  
cancer grant

**8 July 2002**  
Bionomics triples portfolio  
of epilepsy gene  
discoveries (148 gene  
variants, including 98 new  
gene variants, in validated  
drug targets related to CNS  
disorders)

**19 September 2002**  
Over 100 novel  
angiogenesis genes  
advance to  
international patent  
stage

**14 May 2002**  
New epilepsy gene  
discoveries

**9 September 2002**  
World-first animal  
model of inherited  
human epilepsy

# ionX™ Discovery Platform

## Target Identification

Genetic variations associated with epilepsy

## Target Validation

Drug targets  
Screening tools

“Gold Standard” mouse models

## Drug Discovery

New drugs for epilepsy and other CNS disorders

# Research & Development Highlights

**4 December 2001**  
\$1.74 million Federal  
Government breast  
cancer grant

**8 July 2002**  
Bionomics triples portfolio  
of epilepsy gene  
discoveries (148 gene  
variants, including 98 new  
gene variants, in validated  
drug targets related to CNS  
disorders)

**19 September 2002**  
Over 100 novel  
angiogenesis genes  
advance to  
international patent  
stage

**14 May 2002**  
New epilepsy gene  
discoveries

**9 September 2002**  
World-first animal  
model of inherited  
human epilepsy

# Bionomics Scorecard 2001 – 2002

CORPORATE OBJECTIVES	RESULTS
<p><b>Progress gene discoveries into the international patenting phase</b></p>	<p>✓ 3 international PCT patent applications for genes involved in CNS disorders. 1 additional provisional patent application filed in relation to epilepsy gene discoveries.</p> <p>✓ 6 international PCT patent applications for breast cancer</p> <p>✓ 3 provisional patent applications for genes involved in angiogenesis</p>
<p><b>Progress commercial prospects through licensing deals for Bionomics' IP</b></p> <p><i>And</i></p> <p><b>Establish alliances to enhance Bionomics' capacity to compete globally</b></p>	<p>✓ R&amp;D collaboration with Hybrigen Inc., to utilise Hybrigen's proteomic platform to discover drug targets in the areas of angiogenesis and breast cancer. (<i>September 2001/January 2002</i>)</p> <p>✓ Collaboration and license agreement with Genmab A/S to create and develop fully human antibodies to angiogenesis targets identified by Bionomics. (<i>March 2002</i>)</p> <p>✓ Collaboration and licensing agreement with Johnson &amp; Johnson Research Pty Limited (JJR) to validate angiogenesis drug targets and screen JJR compounds. (<i>May 2002</i>)</p>

# Bionomics Scorecard 2001 – 2002

R&D OBJECTIVES	RESULTS
<p><b>Utilise power of Bionomics' gene discovery platform to discover new genes</b></p> <p><i>And</i></p> <p><b>Validate Bionomics' gene discoveries as drug targets or markers for the diagnosis of disease</b></p>	<p>✓ In excess of 148 gene variants, including 98 new gene variants, in validated drug targets related to CNS disorders including epilepsy, Alzheimer's disease and Parkinson's disease.</p> <p>✓ Discovery that BNO64 is a major breast cancer tumour suppressor gene able to block cancer growth.</p> <p>✓ Angiogenesis gene discoveries increased from 56 to 137.</p>

# Significant Achievements Post June 30

- The world's first model of human inherited epilepsy
- License and Collaboration agreement with Nanogen Inc.
- Patent progress – 114 genes from angiogenesis program

# Rapid Progress – Strong Science – Commercial Results

**new treatments & diagnostics**

genetics/genomics platform

functional genomics, proteomics, bioinformatics

drug discovery platforms ionX™ and Angene™

***Commercialising gene discoveries  
to revolutionise medical treatments***

Bionomics

Bionomics

Bionomics  Limited